Form 4 for DGX Quest Diagnostics
Accepted 2026-03-06 00:00:00 ET · period of report 2026-03-04 · accession 0001022079-26-000030 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-06 | 2026-03-04 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | A - Grant | $204.86 | +5,682 | 14.2K | +67% | +$1.16M | |
| 2026-03-06 | 2026-03-04 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | F - Tax | $204.86 | -2,326 | 11.9K | -16% | -$476.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-04 | A | A | 5,682 | $204.86 | 14,190 | D | — | — | (F1) Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock award approved in accordance with the requirements of Rule 16b-3(d). |
| 2 | Common | Common Stock | 2026-03-04 | F | D | 2,326 | $204.86 | 11,864 | D | — | — | (F2) Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock award. |